论文部分内容阅读
目的对Ⅰb型慢性丙肝患者进行抗病毒治疗,研究对其PBMC IL-10、IL-12水平变化的影响。方法选取某院2010年6月~2012年6月期间收治的Ⅰb型慢性丙肝患者100例,所有患者血清HCV-RNA检查均为阳性,使用利巴韦林联合聚乙二醇干扰素α-2a抗病毒治疗48周,检查患者的PBMC IL-12、IL-10水平及谷草转氨酶水平(AST)、谷丙转氨酶(ALT)。结果经过利巴韦林联合聚乙二醇干扰素α-2a抗病毒治疗后,检查患者的PBMC IL-12、IL-10及ALT、AST水平与治疗前相比差异有统计学意义(P<0.05)。结论对于Ⅰb型慢性丙肝患者,给予利巴韦林联合聚乙二醇干扰素α-2a抗病毒治疗效果显著,值得临床应用及推广。
Objective To investigate the effect of antiviral treatment on type Ⅰb chronic hepatitis C patients on the changes of IL-10 and IL-12 in PBMC. Methods A total of 100 patients with type Ⅰb chronic hepatitis C admitted to our hospital from June 2010 to June 2012 were selected. Serum HCV-RNA was positive in all patients. Ribavirin combined with peginterferon alfa-2a After antiviral treatment for 48 weeks, the levels of IL-12 and IL-10 in PBMC of patients and the level of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured. Results After ribavirin and peginterferon alfa-2a antiviral therapy, the levels of IL-12, IL-10, ALT and AST in PBMC of patients were significantly lower than those before treatment (P < 0.05). Conclusion For patients with type Ⅰb chronic hepatitis C, ribavirin combined with peginterferon alfa-2a antiviral therapy is effective, worthy of clinical application and promotion.